Literature DB >> 30395219

Is triple antithrombotic therapy, or rather its duration and composition, the true culprit for the excess of bleeding events observed in patients with atrial fibrillation undergoing coronary intervention?

Felice Gragnano1, Paolo Calabrò2,3, Marco Valgimigli1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30395219     DOI： 10.1093/eurheartj/ehy675

Source DB:  PubMed          Journal:  Eur Heart J        ISSN： 0195-668X            Impact factor:   29.983


× No keyword cloud information.
  4 in total

1.  Choice of antithrombotic therapy for patients with atrial fibrillation undergoing carotid angioplasty and stenting: a nationwide population-based study.

Authors:  Yung-Chuan Huang; Yen-Chun Huang; Yu-Chen Cheng; Mingchih Chen
Journal:  Sci Rep       Date:  2022-01-26       Impact factor: 4.379

2.  Stroke of antiplatelet and anticoagulant therapy in patients with coronary artery disease: a meta-analysis of randomized controlled trials.

Authors:  Qiao Yu Shao; Zhi Jian Wang; Xiao Teng Ma; Xu Ze Lin; Liu Pan; Yu Jie Zhou
Journal:  BMC Cardiovasc Disord       Date:  2021-12-01       Impact factor: 2.298

3.  Non-invasive skin cholesterol testing: a potential proxy for LDL-C and apoB serum measurements.

Authors:  Jiacheng Lai; Yongsheng Han; Chongjian Huang; Bin Li; Jingshu Ni; Meili Dong; Yikun Wang; Qingtong Wang
Journal:  Lipids Health Dis       Date:  2021-10-17       Impact factor: 3.876

4.  First-In-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of SHR2285, a Small-Molecule Factor XIa Inhibitor in Healthy Subjects.

Authors:  Rui Chen; Xiaoduo Guan; Pei Hu; Yanli Dong; Yi Zhu; Tengfei Zhang; Jianjun Zou; Shuyang Zhang
Journal:  Front Pharmacol       Date:  2022-02-10       Impact factor: 5.810
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.